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Multiple sclerosis (MS) is a serious autoimmune demyelinating disease leading to loss
of neurological function. The design and synthesis of various altered peptide ligands of
immunodominant epitopes of myelin proteins to alter the autoimmune response, is a
promising therapeutic approach for MS. In this study, linear and cyclic peptide analogs
based on the myelin basic protein 83–99 (MBP83–99) immunodominant epitope conjugated
to reduced mannan via the (KG)5 and keyhole limpet hemocyanin (KLH) bridge, respectively,
were evaluated for their biological/immunological profiles in SJL/J mice. Of all the pep-
tide analogs tested, linear MBP83–99(F91) and linear MBP83–99(Y91) conjugated to reduced
mannan via a (KG)5 linker and cyclic MBP83–99(F91) conjugated to reduce mannan via KLH
linker, yielded the best immunological profile and constitute novel candidates for further
immunotherapeutic studies against MS in animal models and in human clinical trials.
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INTRODUCTION
Multiple sclerosis (MS) is often a slowly progressive and chronic
auto-immunologically mediated disease of the central nervous sys-
tem (CNS), with inflammation around the myelin sheath (1–3).
MS is primarily a T-helper 1 (Th1)-mediated disease, although
Th17 cells also play a crucial role (4). Experimental autoimmune
encephalomyelitis (EAE) is a commonly used experimental model
of MS and represents an invaluable in vivo model for the evalua-
tion of new immunotherapeutic approaches against MS. There is
clear presence of autoreactive-T cells, which recognize encephali-
togenic epitopes of myelin proteins, such as myelin basic protein
(MBP), myelin oligodendrocyte glycoprotein (MOG), and prote-
olipid protein (PLP). These auto reactive T cells and their secretion
primarily of Th1 cytokines (IFN-gamma) play a pathogenic role
in the induction of disease. One promising immunotherapeutic
approach against MS, involves the design and use of mutated
peptides of immunodominant myelin epitopes to divert Th1 pro-
inflammatory cytokines to an anti-inflammatory state to induce
T cell tolerance. Studies have shown that T cell responses in
patients are associated with the recognition of the 81–105 region
of MBP (Q81DENPVVHFFKNIVTPRTPPPSQGK105), and with
highest affinity and binding to HLA-DR2 (DRA, DRB1*1501)
for MBP83–99 (E83NPVVHFFKNIVTPRTP99) (5–10). Although T
cells from healthy individuals also recognize MBP83–99 the pre-
cursor frequencies are relatively low. The binding of MBP83–99
to HLA-DR2 is via hydrophobic V87 and F90 residues, and, V86,
H88, F89, and K91 being TCR contact residues (10–15). Residue
P96 is also a TCR contact site based on the crystal structure of
HLA-DR2α-MBP89–101 complex (16). In a human phase II clin-
ical trial in MS patients, substitution of the epitope MBP83–99,
with several d-amino acids or Ala at the N terminal (NBI-5788,
CGP77116) induced strong IL-5 and IL-13 cytokine responses;
however, many patients developed dangerous side effects and
the clinical trials were stopped (17, 18). These results indi-
cated that further pre-clinical testing is required and new mod-
ified peptides need to be designed together with appropriate
immunomodulatory adjuvants or carriers, for the peptide based
immunotherapeutic approaches against MS.
Mannan (a poly mannose), which targets the mannose recep-
tor expressed on dendritic cells and macrophages, has been used to
target antigens to dendritic cells to stimulate appropriate immune
responses. Mannan targets antigens to the mannose receptor for
efficient uptake and presentation for T cell stimulation and also
activates dendritic cells via toll-like receptor-4 (19). Whether man-
nan is conjugated to proteins or peptides in its oxidized (com-
prising aldehydes) or reduced (aldehydes reduced to alcohols)
form, both bind to the mannose receptor efficiently; however,
the stimulation of cytokines secreted by dendritic cells varies
considerably, with reduced mannan inducing Th2 cytokines and
oxidized mannan inducing Th1 cytokines (20). In in vivo studies,
mice immunized with oxidized mannan-MUC1 (a tumor associ-
ated antigen) fusion protein are protected against the challenge
of MUC1 expressing tumors, and in established tumors, oxi-
dized mannan-MUC1 is able to reverse established tumors (21,
22). Similarly, in MUC1 transgenic mice oxidized mannan-MUC1
was immunogenic (23). Either a Th1 response (IL-2, IFN-gamma,
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IL-12, TNF-alpha, and IgG2a antibodies) or Th2 response (IL-4,
IL-10, and TGF-beta and IgG1 antibodies) is induced depend-
ing on mode of conjugation, oxidized or reduced mannan (21,
22, 24). Other cytokines (IL-5, IL-6, IL-13, IL-15, and IL-18)
are also secreted with either oxidized or reduced-mannan con-
jugates (24–26). In addition to Th1/Th2 type responses to MUC1
in mice, similar responses have been demonstrated in humans
(27) and monkeys (28) with MUC1 protein and to an Anaplasma
marginale MSP-1 peptide in cows (29). Since reduced mannan
has the ability to induce Th2 responses, it was conceivable to
use reduced-mannan conjugated to MBP peptides, with the idea
being that Th2 cytokines would divert the Th1 cytokines in MS.
Hence, the use of altered peptide ligands (APLs) to alter responses
of the wild type peptide, in combination with reduced mannan
constitutes a novel strategy for the immunotherapy of MS.
We previously demonstrated that linear and cyclic substituted
APLs based on MBP83–99 and MBP87–99 epitopes, with single
or double mutations at positions 91 and 96 as being the cru-
cial TCR contact residues, conjugated to reduced mannan via
the keyhole limpet hemocyanin (KLH) as a linker diverts the
Table 1 | Summary of T cell proliferative, cytokine, and antibody responses.
MBP83–99-(KG)5-peptide analogs-reduced mannan T cell proliferation ELISpot Antibody responses
IFN-γ IL-4 IL-10
1 MannanRed[(KG)5-MBP83–99] +++ +++ − − −
2 MannanRed[(KG)5-MBP83–99(F91)] + − ++ + −
3 MannanRed[(KG)5-MBP83–99(Y91)] + − ++ + −
4 MannanRed[(KG)5-MBP83–99(A88)] ++ ++ − − −
5 MannanRed[(KG)5-MBP83–99(A86)] ++ ++ − − −
Cyclic MBP83–99 peptide analogs-KLH-reduced mannan
6 Cyclo(83–99)MBP83–99(F91) + − ++ + −
7 Cyclo(83–99)MBP83–99(Y91) − +++ + − −
+++, very strong; ++, intermediate; +, weak; −, negative.
FIGURE 1 | Schematic presentation of analog 2: MannanRed[(KG)5-MBP83–99(F91)] and analog 3: MannanRed[(KG)5-MBP83–99(Y91)]. The polarity of each amino
acid is colory presented.
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immune response from Th1 to Th2 enhancing the induction of
anti-inflammatory cytokines IL-4 and IL-10 (30–35). In these
studies, the cyclic and linear APLs were conjugated to KLH fol-
lowed by conjugation to oxidized mannan and followed by its
reduction to result in reduced-mannan conjugates. KLH was used
as a linker between the peptide analogs and mannan as it is known
that KLH has the ability to stimulate/enhance immunity (30–34),
especially the induction of antibody responses. It was shown that
antibodies were highly induced some of which did or did not cross
react with the native peptide (30–34). KLH is a large molecular
weight protein and the conjugate is highly heterogeneous and for
future commercialization prospects following human clinical tri-
als, would be highly complicated. In order to design a more precise
immunotherapeutic with a smaller bridge, between peptide and
reduced mannan, linear mutated MBP83–99 peptide analogs, with
specific TCR substitutions, were conjugated to reduced mannan
via a 10 amino acid bridge, [LysGly]5 [(KG)5] at the N-terminus
of each peptide. In addition, the use of a smaller bridge like (KG)5
rather than KLH could potentially reduce antibody responses
against the immunizing peptide, which could otherwise be a prob-
lem in human clinical trials. In this respect, a number of APL
analogs with (KG)5 at its N-terminus and conjugated to reduced
FIGURE 2 |T cell proliferation of spleen cells from immunized
mice. SJL/J mice were immunized using linear MBP83–99 analogs
conjugated to reduced mannan via (KG)5 bridge (analogs 1–5) and
cyclic MBP83–99 analogs conjugated to reduced mannan via KLH
linker (analogs 6 and 7). ConA (internal positive control) yielded
proliferation of more than 90,000 cpm and was excluded from the
figures and no peptide (cells alone) was used as background
negative control.
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mannan were studied in SJL/J mice for their ability to induce
immune responses, especially, T cell proliferation, IFN-gamma,
IL-4, and IL-10 cytokine secretion and antibody responses.
RESULTS AND DISCUSSION
In this study, we have designed and synthesized mutant peptide
analogs based on the 83–99 epitope of MBP, replacing the Lys at
position 91 with a hydrophobic and aromatic amino acid (Phe or
Tyr) or Val, His at positions 86 and 88 with Ala (Table 1). It is
known that Val88 and Lys91 play a pivotal role in the interaction
with the TCR and the activation of encephalitogenic T cells that
are responsible for EAE and MS induction. The (KG)5 bridge was
used in the N terminal of each linear peptide analog for conjuga-
tion with reduced mannan (Table 1; Figure 1). In our previous
studies, the use of KLH bridge-mannan conjugates was less stable
compared with reduced-mannan conjugation via (KG)5 bridge.
Two cyclic analogs were also synthesized with head-to-tail cycliza-
tion and mutation at position 91 (Phe or Tyr). The cyclic peptide
analogs 6, 7 were conjugated with mannan via the KLH linker. It
is known that the cyclic analogs are more stable in proteolytic
degradation compared to linear counterparts (36). The back-
bone cyclization of peptides has been demonstrated to improve
biological activity, in vivo stability and to reduce conformation
freedom (37).
SJL/J mice (I–As) is commonly used for the evaluation of MBP
peptide analogs, as both murine I–As and human HLA-DR2 bind
to MBP83–99 peptides. The synthesized MBP83–99-(KG)5 analogs
conjugated to reduced mannan were used to immunize SJL/J mice.
Immunized mice with analog 1, induced very strong T cell prolif-
erative responses after recall peptide in vitro. Peak proliferation
was on day 2, which declined by day 3 (p< 0.001), and were
background levels by day 4. Analogs 4 and 5 induced interme-
diate T cell proliferative responses (p< 0.001). Analogs 2, 3, and
6, induced weak T cell proliferative responses, which were specific
and significantly above background levels (p< 0.001). Peptide 7
did not stimulate T cell responses in SJL/J mice (Table 1; Figure 2).
FIGURE 3 | IFN-gamma ELISpot assay of spleen cells from immunized
mice. SJL/J mice were immunized using linear MBP83–99 analogs conjugated
to reduced mannan via (KG)5 bridge (analogs 1–5) and cyclic MBP83–99 analogs
conjugated to reduced mannan via KLH linker (analogs 6 and 7). No peptide
(cells alone) was used as background negative control. ConA was used as an
internal positive control to ensure cells were reactive, not shown.
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Spleen cells were isolated and assessed for T cell cytokine
production (IFN-gamma, IL-4, IL-10) using the ELISpot assay
(Table 1; Figures 3–5). Immunized mice with analogs 1 and 7
induced very strong IFN-gamma cytokine responses after recall
peptide in vitro (p< 0.001). Analogs 4 and 5 induced intermedi-
ate IFN-gamma cytokine responses (p< 0.001). Analogs 2, 3, and
6 did not stimulate IFN-gamma cytokine responses in SJL/J mice
(Figure 3). Immunized mice with analogs 2, 3, and 6 induced inter-
mediate IL-4 cytokine responses (p< 0.001). Analog 7 induced
weak IL-4 cytokine response, which was significant above back-
ground. Analogs 1, 4, and 5 did not stimulate IL-4 cytokine
responses in SJL/J mice (Figure 4). Moreover, analogs 2, 3, and
6 induced very weak IL-10 cytokine response, which were sig-
nificant above background (p< 0.05). All other peptides did not
stimulate IL-4 cytokine responses in SJL/J mice (Figure 5). Inter-
estingly, none of the peptide analogs generated antibody responses
as measured by reactivity to native peptide and to peptide analog,
from serum from immunized mice (Table 1).
CONCLUSION
In previous studies, we used KLH as a linker between mannan
and linear peptide. However, in an attempt to develop more
defined conjugates for clinical use, we used a small 10 amino
acid bridge (KG)5, to link mannan to linear APL. In this regard,
the mannanRed[(KG)5-MBP83–99] analog (native epitope) induced
very strong T cell proliferative and IFN-gamma cytokine secre-
tion responses. The mannanRed[(KG)5-MBP83–99(F91)] and cyclic
MBP83–99(F91) did not induce IFN-gamma responses and anti-
bodies but induced IL-4 and IL-10 cytokines. The mannanRed
[(KG)5-MBP83–99(Y91)] did not induce IFN-gamma responses
and antibodies but induced IL-4 and IL-10 cytokine; how-
ever, the cyclic counterpart cyclo(83–99)MBP83–99(Y91) generated
strong IFN-γ cytokine the same as for the mannanRed[(KG)5-
MBP83–99(A88)] and mannanRed[(KG)5-MBP83–99(A86)]. None
of the peptide analogs generated antibody responses. Of note,
here we used KLH as a linker between mannan and cyclic
peptide, as (KG)5 bridge would not allow conjugation in the
FIGURE 4 | IL-4 ELISpot assay of spleen cells from immunized mice.
SJL/J mice were immunized using linear MBP83–99 analogs conjugated to
reduced mannan via (KG)5 bridge (analogs 1–5) and cyclic MBP83–99 analogs
conjugated to reduced mannan via KLH linker (analogs 6 and 7). No peptide
(cells alone) was used as background negative control. ConA was used as an
internal positive control to ensure cells were reactive, not shown.
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FIGURE 5 | IL-10 ELISpot assay of spleen cells from immunized mice.
SJL/J mice were immunized using linear MBP83–99 analogs conjugated to
reduced mannan via (KG)5 bridge (analogs 1–5) and cyclic MBP83–99 analogs
conjugated to reduced mannan via KLH linker (analogs 6 and 7). No peptide
(cells alone) was used as background negative control. ConA was used as an
internal positive control to ensure cells were reactive, not shown.
cyclic peptide form. In conclusion, the analogs 1, 2, and 6,
mannanRed[(KG)5-MBP83–99(F91)], cyclic MBP83–99(F91), and
linear mannanRed[(KG)5-MBP83–99(Y91)], respectively, yielded
the best immunological profile (Table 1) and are the most promis-
ing candidates for further studies in vivo in EAE studies, in
humanized mice and in vitro using human T cell clones spe-
cific for MBP83–99 immunodominant epitope. Similar to our
previous studies, using KLH as a linker between mannan and
linear peptides, the more defined (KG)5 bridge presented here,
induce specific immune responses. These peptides constitute novel
analogs for further immunotherapeutic studies in animal models
and possibly in human clinical trials.
EXPERIMENTAL PROCEDURES
SOLID PHASE PEPTIDE SYNTHESIS OF LINEAR AND CYCLIC ANALOGS
Peptides (Table 1) were synthesized under microwave irradi-
ation conditions (38, 39), following the Fmoc/tBu methodol-
ogy, using the standard the N,N ′-diisopropyl-carbodiimide (DIC)
and 1-hydroxybenzotriazol (HOBt) as coupling reagents (40–43).
The head-to-tail cyclization of analogs 6 and 7 was achieved using
O-benzotriazol-1-yl-N,N,N ′,N ′-tetramethyluronium tetrafluoro
borate/1-hydroxy 7-azabenzotriazol (TBTU/HOAt) and 2,4,6-
collidine in dry dimethyformamide (DMF) (Schemes 1 and 2)
(36, 41–45). The final peptides were further purified using semi-
preparative reverse phase high performance liquid chromatogra-
phy (RP-HPLC). The purity of peptides was higher than 98%
as determined by analytical RP-HPLC and their identification
was achieved by electron spray ionization mass spectrometry
(ESI-MS).
CONJUGATION OF REDUCED MANNAN TO LINEAR AND CYCLIC
MBP83–99 PEPTIDE ANALOGS
The conjugation between peptide to reduced mannan was
achieved following a protocol earlier described for protein or
peptide-KLH conjugations (21, 22, 31, 34). Briefly, 14 mg man-
nan (poly mannose from Saccharomyces cerevisiae, Sigma-Aldrich
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SCHEME 1 | Synthetic procedure of linear peptide analogs based on the MBP83–99 immunodominant epitope.
Ltd., was dissolved in 1 ml phosphate buffer, pH 6.0, and oxidized
to polyaldehyde by treating with sodium periodate. Ethanediol was
then added to the mixture and the mixture was passed through a
PD-10 column (Sephadex G-25 M column, Pharmacia Biotech.,
Sweden) equilibrated with 0.1 M bicarbonate buffer pH 9.0 and the
oxidized mannan fraction collected. Conjugation of linear peptide
analogs-(KG)5 (analogs 1–5) and cyclic analogs-KLH (analogs 6
and 7) to oxidized mannan was performed in bicarbonate buffer,
pH 9.0, in dark (Table 1; Figure 1). The addition of sodium boro-
hydride for 6 h at room temperature resulted in reduced-mannan
conjugates (46). The final MBP peptide analogs conjugated with
mannan were analyzed by SDS PAGE (44).
MICE AND IMMUNIZATIONS
Female 6- to 8-week-old SJL/J mice, used in all experiments, were
purchased from Walter and Eliza Hall Institute (VIC, Australia)
and housed at the Biological Research Laboratory at Burnet Insti-
tute (Austin Campus), Heidelberg, VIC, Australia. SJL/J mice were
immunized with 50µg of each peptide analog (Table 1) conju-
gated with reduced mannan, twice on days 0 and 14, intradermally
(at the base of the tail). All studies were reviewed and approved by
Austin Health and Alfred Health animal ethics committee.
IMMUNOLOGICAL ASSAYS
ELISpot
Spleen cells from immunized SJL/J mice were isolated 14 days
after the last immunization and assessed by ELISpot for IFN-γ,
IL-4, and IL-10 secretion by T cells. IFN-γ ELISpot assay was
performed on MultiScreen-IP Filter Plate (MAIP S4510) with
hydrophobic PVDF filters (Millipore, UK), while IL-4 and IL-10
ELISpot assays were performed on MultiScreen-HA Filter Plate
(MAHA S4510) with mixed cellulose esters filters (Millipore, UK).
MAIP S4510 plates were pre-wetted with 50µl of 70% ethanol,
washed five times with 200µl of sterile phosphate buffered saline
(PBS) and coated with 70µl of 5µg/ml anti-IFN-γ capture anti-
body, AN18 (Mabtech, Australia) in PBS and incubated at 4°C
overnight (O/N). Seventy microliters of 5µg/ml anti-IL-4 cap-
ture antibody (Mabtech, Australia) were added directly to MAHA
S4510 plates and incubated at 4°C O/N without 70% ethanol treat-
ment. Following five washes with PBS, plates were blocked by
adding 200µl of culture media (supplemented with 2.5% FCS)
and incubated for 2 h at 37°C. The blocking media was discarded
and 10µg/ml recall peptides were added into each defined well.
Con A (1.0µg/ml) was used as internal positive control and no
peptide (cells alone) as negative control. Triplicate wells were set
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SCHEME 2 | Synthetic procedure of cyclic peptide analogs based on the MBP83–99 immunodominant epitope.
up for each condition. About 5× 105 spleen cells in 100µl culture
media were seeded into each well and incubated at 37°C for 18 h
(IFN-γ), or 24 h (IL-4), or 48 h for IL-10. Plates were washed five
times with PBS/0.05% Tween 20 followed by five times with PBS
and incubated for 2 h at RT with anti-murine IFN-γ, IL-4, or IL-10
monoclonal antibody-biotin. Plates were washed and streptavidin
alkaline phosphatase (streptavidin–ALP) was added at 1.0µg/ml
and incubated for 2 h at RT. Spots of activity were detected using a
colorimetric AP kit (Biorad, Hercules, CA USA) and counted using
an AID ELISpot plate reader (Autoimmun Diagnostika GmbH,
Germany). Data are presented as mean spot forming units (SFU)
per 0.5× 106 cells±SEM.
Proliferation
Spleen cells from immunized SJL/J mice were isolated 25–28 days
after immunization and assessed by T cell proliferation assay.
About 1× 105 spleen cells in 100µl of culture media were seeded
into 96 well U -bottom plates and incubated for 1–6 days at 37°C
in the presence of recall peptide (10µg/ml), ConA (internal con-
trol), or no peptide (negative control). ConA (internal positive
control) yielded proliferation of more than 90,000 cpm and was
excluded from the figures and no peptide (cells alone) was used
as background negative control. Proliferation was assessed by
adding 1µCi of [3H]-thymidine per well to one plate per time
point (days 1–6). Cells were incubated for 6 h before harvest-
ing onto glass fiber filters. [3H]-thymidine uptake was measured
using a β-scintillation counter (Top Count Gamma Counter,
Packard, USA).
Statistical analysis
Mean values were compared using an unpaired t -test and one-way
ANOVA. *p< 0.05 indicates a significant difference, **p< 0.001
indicates highly significant difference.
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